NL301058I2 - Brolucizumab - Google Patents

Brolucizumab Download PDF

Info

Publication number: NL301058I2
Authority: NL; Netherlands
Prior art keywords: brolucizumab
Prior art date: 2008-06-25

Application number

NL301058C

Other languages

English (en)

Other versions

NL301058I1 (nl

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-06-25

Filing date

2020-07-28

Publication date

2020-10-27

2020-07-28 Application filed by Novartis Ag filed Critical Novartis Ag

2020-07-31 Publication of NL301058I1 publication Critical patent/NL301058I1/nl

2020-10-27 Publication of NL301058I2 publication Critical patent/NL301058I2/nl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Ophthalmology & Optometry (AREA)
Reproductive Health (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Zoology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Tropical Medicine & Parasitology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)

NL301058C 2008-06-25 2020-07-28 Brolucizumab NL301058I2 (nl)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US13321208P	2008-06-25	2008-06-25
US7569708P	2008-06-25	2008-06-25
US7569208P	2008-06-25	2008-06-25
US15504109P	2009-02-24	2009-02-24
PCT/CH2009/000220 WO2009155724A2 (en)	2008-06-25	2009-06-25	Stable and soluble antibodies inhibiting vegf

Publications (2)

Publication Number	Publication Date
NL301058I1 NL301058I1 (nl)	2020-07-31
NL301058I2 true NL301058I2 (nl)	2020-10-27

Family

ID=41209803

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL301058C NL301058I2 (nl)	2008-06-25	2020-07-28	Brolucizumab

Country Status (26)

Country	Link
US (6)	US8349322B2 (nl)
EP (3)	EP3722310B1 (nl)
JP (7)	JP5956752B2 (nl)
KR (8)	KR102013220B1 (nl)
CN (3)	CN102143976B (nl)
AU (1)	AU2009264565C1 (nl)
BR (1)	BRPI0914251B1 (nl)
CA (2)	CA3020290A1 (nl)
CL (1)	CL2010001544A1 (nl)
CY (3)	CY1118829T1 (nl)
DK (3)	DK2307454T3 (nl)
ES (3)	ES2622470T3 (nl)
FI (1)	FI3722310T3 (nl)
HR (3)	HRP20241467T1 (nl)
HU (4)	HUE068894T2 (nl)
LT (4)	LT2307454T (nl)
MX (3)	MX392435B (nl)
NL (1)	NL301058I2 (nl)
NO (1)	NO2020021I1 (nl)
PH (1)	PH12015501593A1 (nl)
PL (3)	PL3216803T3 (nl)
PT (3)	PT2307454T (nl)
RU (6)	RU2588467C3 (nl)
SI (3)	SI2307454T1 (nl)
WO (1)	WO2009155724A2 (nl)
ZA (1)	ZA201008594B (nl)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ571300A (en)	2006-04-07	2011-12-22	Warner Chilcott Co Llc	Antibodies that bind human protein tyrosine phosphatase beta (HPTPBeta) and uses thereof
WO2009155723A2 (en)	2008-06-25	2009-12-30	Esbatech, An Alcon Biomedical Research Unit Llc	STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
ES2677003T3 (es)	2008-06-25	2018-07-27	Esbatech, An Alcon Biomedical Research Unit Llc	Humanización de anticuerpos de conejo utilizando un marco universal de anticuerpos
KR102013220B1 (ko) *	2008-06-25	2019-08-23	에스바테크 - 어 노바티스 컴파니 엘엘씨	Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체
MX344076B (es) *	2008-06-30	2016-12-05	Esbatech Alcon Biomed Res Unit	Polipeptidos funcionalizados.
US8268314B2 (en)	2008-10-08	2012-09-18	Hoffmann-La Roche Inc.	Bispecific anti-VEGF/anti-ANG-2 antibodies
JP5764071B2 (ja)	2009-02-24	2015-08-12	エスバテック − アノバルティスカンパニーエルエルシー	細胞表面抗原のイムノバインダーを同定するための方法
SG176963A1 (en)	2009-06-22	2012-02-28	Amgen Inc	Refolding proteins using a chemically controlled redox state
EP3660032B1 (en)	2009-06-25	2025-10-22	Amgen Inc.	Capture purification processes for proteins expressed in a non-mammalian system
CA3037903A1 (en) *	2010-10-09	2012-04-26	Mayo Foundation For Medical Education & Research	Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
AR083495A1 (es)	2010-10-22	2013-02-27	Esbatech Alcon Biomed Res Unit	Anticuerpos estables y solubles
US9527925B2 (en)	2011-04-01	2016-12-27	Boehringer Ingelheim International Gmbh	Bispecific binding molecules binding to VEGF and ANG2
SG11201400193SA (en) *	2011-09-16	2014-05-29	Ucb Pharma Sa	Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
CA2850830A1 (en)	2011-10-13	2013-04-18	Aerpio Therapeutics, Inc.	Methods for treating vascular leak syndrome and cancer
EP2809344B1 (en)	2012-02-02	2016-08-24	ESBATech - a Novartis Company LLC	Antibody-containing sustained-release formulation for ocular administration
RS62509B1 (sr)	2012-07-13	2021-11-30	Roche Glycart Ag	Bispecifična anti-vegf/anti-ang-2 antitela i njihova upotreba u lečenju očnih vaskularnih bolesti
CN104995303A (zh)	2012-12-18	2015-10-21	诺华股份有限公司	利用结合乙酰透明质酸的肽标签的组合物和方法
AU2014218318B2 (en)	2013-02-18	2018-02-15	Vegenics Pty Limited	Ligand binding molecules and uses thereof
KR101541478B1 (ko) *	2013-05-31	2015-08-05	동아쏘시오홀딩스 주식회사	항-vegf 항체 및 이를 포함하는 암 또는 신생혈관형성관련 질환의 예방, 진단 또는 치료용 약학 조성물
IL243311B (en) *	2013-06-26	2022-07-01	Numab Therapeutics AG	New frameworks for antibodies
EP4374873B1 (en)	2013-07-12	2025-10-22	Astellas US LLC	Agent for use in treating or preventing opthalmological conditions
WO2015076425A1 (ja) *	2013-11-25	2015-05-28	リンク・ジェノミクス株式会社	新規モノクローナル抗体
KR20170003973A (ko)	2014-05-12	2017-01-10	포르미콘 아게	Ｖｅｇｆ 안타고니스트를 포함하는 사전충전형 플라스틱제 주사기
WO2015198243A2 (en)	2014-06-25	2015-12-30	Novartis Ag	Compositions and methods for long acting proteins
EP3160991A2 (en)	2014-06-25	2017-05-03	Novartis AG	Compositions and methods for long acting proteins
US9840553B2 (en)	2014-06-28	2017-12-12	Kodiak Sciences Inc.	Dual PDGF/VEGF antagonists
GB201412658D0 (en)	2014-07-16	2014-08-27	Ucb Biopharma Sprl	Molecules
KR102390359B1 (ko)	2014-09-29	2022-04-22	삼성전자주식회사	폴리펩타이드, 이를 포함하는 항 VEGF 항체 및 항 c-Met/항 VEGF 이중 특이 항체
TWI705827B (zh) *	2014-11-07	2020-10-01	瑞士商諾華公司	治療眼部疾病之方法
EP3218403B1 (en)	2014-11-10	2020-05-13	F.Hoffmann-La Roche Ag	Anti-interleukin-33 antibodies and uses thereof
EP3250596A1 (en)	2015-01-28	2017-12-06	Pfizer Inc	Stable aqueous anti- vascular endothelial growth factor (vegf) antibody formulation
JP6917899B2 (ja)	2015-04-16	2021-08-11	ハー・ルンドベック・アクチエゼルスカベット	抗ｐａｃａｐ抗体及びそれらの使用
US10851399B2 (en) *	2015-06-25	2020-12-01	Native Microbials, Inc.	Methods, apparatuses, and systems for microorganism strain analysis of complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon
GB201601077D0 (en)	2016-01-20	2016-03-02	Ucb Biopharma Sprl	Antibody molecule
GB201601073D0 (en) *	2016-01-20	2016-03-02	Ucb Biopharma Sprl	Antibodies
ES2913530T3 (es)	2015-08-12	2022-06-02	Novartis Ag	Métodos para tratar trastornos oftálmicos
MA43113B1 (fr)	2015-10-30	2021-06-30	Hoffmann La Roche	Anticorps anti-htr a1 et méthodes d'utilisation de ceux-ci
JP6985572B2 (ja) *	2015-11-09	2021-12-22	国立大学法人京都工芸繊維大学	単鎖抗体のスクリーニング方法及び単鎖抗体
AU2016358111B2 (en)	2015-11-18	2021-11-18	Sio2 Medical Products, Llc	Pre-filled pharmaceutical package comprising a liquid formulation of a VEGF-antagonist
WO2018218013A2 (en)	2017-05-24	2018-11-29	Sio2 Medical Products, Inc.	Sterilizable pharmaceutical package for ophthalmic formulations
KR102854749B1 (ko)	2015-11-18	2025-09-04	에스아이오2 메디컬 프로덕츠, 엘엘씨	안과 제제용 제약 패키지
EP3377151A1 (en)	2015-11-18	2018-09-26	Formycon AG	Pre-filled plastic syringe containing a vegf antagonist
GB201521389D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl	Method
GB201521382D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl	Antibodies
JP7088454B2 (ja)	2015-12-30	2022-06-21	コディアックサイエンシーズインコーポレイテッド	抗体および抗体複合体
JP6925981B2 (ja)	2016-01-06	2021-08-25	株式会社オーダーメードメディカルリサーチ	Ｖｅｇｆとｎｒｐ１との結合を阻害する抗体
WO2017119435A1 (ja)	2016-01-06	2017-07-13	株式会社オーダーメードメディカルリサーチ	高親和性抗ｖｅｇｆ抗体
USD789171S1 (en)	2016-01-21	2017-06-13	Nomis Llc	Right angle drive
US10576128B2 (en)	2016-01-26	2020-03-03	Formycon Ag	Liquid formulation of a VEGF antagonist
EP3411070A4 (en)	2016-02-05	2019-11-27	The Board of Regents of The University of Texas System	EGFL6-SPECIFIC MONOCLONAL ANTIBODIES AND METHODS FOR THEIR USE
WO2017156423A2 (en) *	2016-03-11	2017-09-14	Integrated Biotherapeutics, Inc.	Broadly protective antibody cocktails for treatment of filovirus hemorrhagic fever
EP3222673A1 (de) *	2016-03-23	2017-09-27	LANXESS Deutschland GmbH	Metallazopigmente
CN109311977B (zh) *	2016-04-15	2022-06-14	H.伦德贝克公司	人源化的抗pacap抗体及其用途
PH12018502670B1 (en)	2016-06-30	2023-03-24	Celltrion Inc	Stable liquid pharmaceutical preparation
JP7050702B2 (ja)	2016-07-08	2022-04-08	ジェネンテック，インコーポレイテッド	Ｎｒｆ２及びその遺伝子の下流標的遺伝子の発現状態及び変異状態によるがんの診断及び治療方法
WO2018162724A1 (en) *	2017-03-09	2018-09-13	Mab Discovery Gmbh	Antibodies specifically binding to human il-1r7
JOP20190245A1 (ar)	2017-04-20	2019-10-15	Novartis Ag	أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
EP3624847A1 (en)	2017-05-19	2020-03-25	Council of Scientific and Industrial Research	A method for producing refolded recombinant humanized ranibizumab
WO2018215580A1 (en)	2017-05-24	2018-11-29	Formycon Ag	Method for sterilizing prefilled plastic syringes containing a vegf antagonist
US20200237997A1 (en)	2017-05-24	2020-07-30	Formycon Ag	Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
EP3645048A4 (en) *	2017-06-25	2021-06-16	Systimmune, Inc.	MULTISPECIFIC ANTIBODIES AND THE METHOD OF MANUFACTURING AND USING THEREOF
WO2019020777A1 (en)	2017-07-26	2019-01-31	Formycon Ag	LIQUID FORMULATION OF A VEGF ANTAGONIST
CA3083472A1 (en)	2017-11-27	2019-05-31	4D Molecular Therapeutics Inc.	Adeno-associated virus variant capsids and use for inhibiting angiogenesis
JP7436365B2 (ja)	2017-12-29	2024-02-21	エフ．ホフマン－ラロシュアーゲー	抗ｖｅｇｆ抗体及び使用の方法
WO2019143837A1 (en) *	2018-01-17	2019-07-25	Apexigen, Inc.	Anti-pd-l1 antibodies and methods of use
JP2021514656A (ja)	2018-03-02	2021-06-17	コディアックサイエンシーズインコーポレイテッドＫｏｄｉａｋＳｃｉｅｎｃｅｓＩｎｃ．	Ｉｌ−６抗体ならびにその融合構築物およびコンジュゲート
KR20200131839A (ko)	2018-03-16	2020-11-24	노파르티스 아게	안질환의 치료 방법
CN118846040A (zh) *	2018-04-06	2024-10-29	伊莱利利公司	用于治疗儿科患者中的癌症的雷莫芦单抗
NZ772550A (en)	2018-08-30	2025-08-29	Immunitybio Inc	Multi-chain chimeric polypeptides and uses thereof
KR20210069639A (ko)	2018-08-30	2021-06-11	에이치씨더블유 바이올로직스, 인크.	단일-사슬 키메라 폴리펩타이드 및 이의 용도
CN120267819A (zh)	2018-08-30	2025-07-08	免疫生物公司	治疗老年化相关病症的方法
KR20210061341A (ko) *	2018-09-13	2021-05-27	더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템	신규한 lilrb4 항체 및 이의 용도
CN120058958A (zh)	2018-09-24	2025-05-30	视点制药公司	靶向HPTP-β（VE-PTP）和VEGF的多特异性抗体
JP7089121B2 (ja)	2018-12-18	2022-06-21	ノバルティスアーゲー	高濃度の抗ｖｅｇｆ抗体を含有するタンパク質溶液製剤
USD907455S1 (en)	2019-05-21	2021-01-12	Nomis Llc	Right angle drive attachment
USD907456S1 (en)	2019-05-21	2021-01-12	Nomis Llc	Right angle drill attachment
US11738052B2 (en)	2019-06-21	2023-08-29	HCW Biologics, Inc.	Multi-chain chimeric polypeptides and uses thereof
CA3149706A1 (en)	2019-09-13	2021-03-18	Novartis Ag	Methods for treating ocular diseases
EP4041312A4 (en)	2019-10-10	2023-12-20	Kodiak Sciences Inc.	METHOD FOR TREATING AN EYE DISORDER
US20230080224A1 (en) *	2020-02-07	2023-03-16	Agency For Science, Technology And Research	Antigen-binding molecules against alppl2 and/or alpp and uses thereof
EP4103599A1 (en)	2020-02-11	2022-12-21	HCW Biologics, Inc.	Methods of activating regulatory t cells
CN115362169A (zh)	2020-02-11	2022-11-18	Hcw生物科技公司	色谱树脂以及其用途
CA3169231A1 (en)	2020-02-11	2021-08-19	HCW Biologics, Inc.	Methods of treating age-related and inflammatory diseases
WO2021174127A1 (en) *	2020-02-28	2021-09-02	Apexigen, Inc.	Anti-sirpa antibodies and methods of use
CA3175140A1 (en) *	2020-03-12	2021-09-16	Immune-Onc Therapeutics, Inc.	Novel anti-lilrb4 antibodies and derivative products
IL296256A (en)	2020-03-13	2022-11-01	Genentech Inc	Anti-interleukin-33 antibodies and uses thereof
US12497462B2 (en)	2020-04-29	2025-12-16	Immunitybio, Inc.	Anti-CD26 proteins and uses thereof
WO2021247003A1 (en)	2020-06-01	2021-12-09	HCW Biologics, Inc.	Methods of treating aging-related disorders
EP4157460A1 (en)	2020-06-01	2023-04-05	HCW Biologics, Inc.	Methods of treating aging-related disorders
US12024545B2 (en)	2020-06-01	2024-07-02	HCW Biologics, Inc.	Methods of treating aging-related disorders
PE20231093A1 (es)	2020-07-16	2023-07-18	Novartis Ag	Anticuerpos anti-betacelulina, fragmentos de los mismos, y moleculas de union multiespecificas
AU2021361108A1 (en)	2020-10-15	2023-05-25	F. Hoffmann-La Roche Ag	Non-covalent protein-hyaluronan conjugates for long-acting ocular delivery
TW202237181A (zh)	2020-11-25	2022-10-01	瑞士商諾華公司	治療眼部疾病之方法
WO2022201084A1 (en)	2021-03-26	2022-09-29	Novartis Ag	Methods for treating ocular diseases
EP4329734A4 (en)	2021-04-26	2025-04-02	Celanese EVA Performance Polymers LLC	Implantable device for the delayed release of a macromolecular drug compound
EP4145456A1 (en)	2021-09-06	2023-03-08	Bayer AG	Prediction of a change related to a macular fluid
KR102809807B1 (ko)	2021-12-21	2025-05-16	한림대학교 산학협력단	항-cldn18.2를 포함하는 키메릭 항원 수용체를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 및 이의 제조 방법
EP4486368A1 (en)	2022-03-02	2025-01-08	ImmunityBio, Inc.	Method of treating pancreatic cancer
TW202337496A (zh)	2022-03-17	2023-10-01	瑞士商諾華公司	治療新生血管性年齡相關性黃斑點退化之方法
CN117820474A (zh) *	2023-04-25	2024-04-05	南京贝思奥生物科技有限公司	改善眼部血管新生相关疾病的药物及其应用
CN117069848B (zh) *	2023-08-02	2025-02-28	武汉爱博泰克生物科技有限公司	抗人cd146兔单克隆抗体及其应用

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4275149A (en)	1978-11-24	1981-06-23	Syva Company	Macromolecular environment control in specific receptor assays
US4376110A (en)	1980-08-04	1983-03-08	Hybritech, Incorporated	Immunometric assays using monoclonal antibodies
US4737456A (en)	1985-05-09	1988-04-12	Syntex (U.S.A.) Inc.	Reducing interference in ligand-receptor binding assays
US6548640B1 (en)	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US4881175A (en)	1986-09-02	1989-11-14	Genex Corporation	Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en)	1986-09-02	1993-11-09	Enzon, Inc.	Single polypeptide chain binding molecules
US5013653A (en)	1987-03-20	1991-05-07	Creative Biomolecules, Inc.	Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5091513A (en)	1987-05-21	1992-02-25	Creative Biomolecules, Inc.	Biosynthetic antibody binding sites
JPH02500329A (ja)	1987-05-21	1990-02-08	クリエイテイブ・バイオマリキユールズ・インコーポレーテツド	ターゲット化多機能蛋白質
US5258498A (en)	1987-05-21	1993-11-02	Creative Biomolecules, Inc.	Polypeptide linkers for production of biosynthetic proteins
US5132405A (en)	1987-05-21	1992-07-21	Creative Biomolecules, Inc.	Biosynthetic antibody binding sites
JP3040121B2 (ja)	1988-01-12	2000-05-08	ジェネンテク，インコーポレイテッド	増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5147638A (en)	1988-12-30	1992-09-15	Oklahoma Medical Research Foundation	Inhibition of tumor growth by blockade of the protein C system
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
OA10149A (en)	1991-03-29	1996-12-18	Genentech Inc	Vascular endothelial cell growth factor antagonists
US6582959B2 (en)	1991-03-29	2003-06-24	Genentech, Inc.	Antibodies to vascular endothelial cell growth factor
DE122004000008I1 (de)	1991-06-14	2005-06-09	Genentech Inc	Humanisierter Heregulin Antikörper.
EP1238986B1 (en)	1992-10-28	2008-06-25	Genentech, Inc.	Use of Vascular endothelial cell growth factor antagonists
IL117645A (en)	1995-03-30	2005-08-31	Genentech Inc	Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5730977A (en)	1995-08-21	1998-03-24	Mitsui Toatsu Chemicals, Inc.	Anti-VEGF human monoclonal antibody
CN1300173C (zh)	1996-02-09	2007-02-14	艾博特生物技术有限公司	结合人TNFα的人抗体
DE69726003T2 (de) *	1996-07-16	2004-08-26	Andreas Plückthun	Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit
WO2000053760A2 (en) *	1999-03-12	2000-09-14	Genentech, Inc.	Method of preventing the death of retinal neurons and treating ocular diseases
US6986890B1 (en)	1996-11-21	2006-01-17	Kyowa Hakko Kogyo Co., Ltd.	Anti-human VEGF receptor Flt-1 monoclonal antibody
US20020032315A1 (en)	1997-08-06	2002-03-14	Manuel Baca	Anti-vegf antibodies
US7365166B2 (en)	1997-04-07	2008-04-29	Genentech, Inc.	Anti-VEGF antibodies
DK1325932T5 (da) *	1997-04-07	2005-10-03	Genentech Inc	Anti-VEGF antistoffer
SI0973804T1 (sl) *	1997-04-07	2007-06-30	Genentech Inc	Proti-VEGF protitelesa
WO2000034337A1 (en)	1998-12-10	2000-06-15	Tsukuba Research Laboratory, Toagosei Co., Ltd.	Humanized monoclonal antibodies against vascular endothelial cell growth factor
IL145941A (en)	1999-04-28	2007-08-19	Univ Texas	Compositions and methods for cancer treatment by selectively inhibiting vegf
US6703020B1 (en)	1999-04-28	2004-03-09	Board Of Regents, The University Of Texas System	Antibody conjugate methods for selectively inhibiting VEGF
JP2003527334A (ja) *	1999-10-22	2003-09-16	ルードヴィッヒインスティテュートフォーキャンサーリサーチ	Ａ３３抗原特異的免疫グロブリン産物を用いるａ３３抗原を発現する癌の影響を低減する方法
EP1242457B1 (en)	1999-12-28	2004-08-11	Esbatech AG	Intrabodies with defined framework that is stable in a reducing environment and applications thereof
GB0013810D0 (en)	2000-06-06	2000-07-26	Celltech Chiroscience Ltd	Biological products
US7667004B2 (en)	2001-04-17	2010-02-23	Abmaxis, Inc.	Humanized antibodies against vascular endothelial growth factor
DE10201450B4 (de)	2002-01-16	2004-09-02	Infineon Technologies Ag	Carry-Skip-Addierer für verschlüsselte Daten
US6576941B1 (en)	2002-02-20	2003-06-10	Samsung Electronics Co., Ltd.	Ferroelectric capacitors on protruding portions of conductive plugs having a smaller cross-sectional size than base portions thereof
CN1187373C (zh) *	2002-03-20	2005-02-02	上海中信国健药业有限公司	人源化抗血管内皮生长因子单克隆抗体及其制法和药物组合物
WO2003080672A1 (en)	2002-03-22	2003-10-02	Aprogen, Inc.	Humanized antibody and process for preparing same
PT2332989E (pt) *	2002-05-22	2015-08-05	Esbatech Alcon Biomed Res Unit	Estruturas de imunoglobulina que demonstram estabilidade aumentada no ambiente intracelular e métodos de identificação das mesmas
US20040086979A1 (en)	2002-08-15	2004-05-06	Dongxiao Zhang	Humanized rabbit antibodies
RS20170595A1 (sr)	2003-05-30	2017-09-29	Genentech Inc	Tretman sa anti-vegf antitelima
US20050048578A1 (en) *	2003-06-26	2005-03-03	Epitomics, Inc.	Methods of screening for monoclonal antibodies with desirable activity
US7758859B2 (en)	2003-08-01	2010-07-20	Genentech, Inc.	Anti-VEGF antibodies
US20050106667A1 (en)	2003-08-01	2005-05-19	Genentech, Inc	Binding polypeptides with restricted diversity sequences
WO2005044853A2 (en) *	2003-11-01	2005-05-19	Genentech, Inc.	Anti-vegf antibodies
US20050033031A1 (en) *	2003-08-07	2005-02-10	Couto Fernando Jose Rebelo Do	Methods for humanizing rabbit monoclonal antibodies
AU2005269265B2 (en)	2004-08-02	2012-01-12	Zenyth Operations Pty Ltd	A method of treating cancer comprising a VEGF-B antagonist
HRP20120902T1 (hr)	2004-10-21	2012-12-31	Genentech, Inc.	Postupak lijeäśenja bolesti intraokularne neovaskularizacije
US7462697B2 (en) *	2004-11-08	2008-12-09	Epitomics, Inc.	Methods for antibody engineering
US7431927B2 (en)	2005-03-24	2008-10-07	Epitomics, Inc.	TNFα-neutralizing antibodies
JP2009504685A (ja) *	2005-08-15	2009-02-05	アラーナ・テラピューティクス・リミテッド	新世界霊長類フレームワーク領域を用いる設計された抗体
AR059066A1 (es)	2006-01-27	2008-03-12	Amgen Inc	Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
WO2007140534A1 (en) *	2006-06-08	2007-12-13	Csl Limited	Vegf-a cross-reactive anti- vegf-b antibodies as antagonists of vegf-a and vegf-b signalling
LT2046382T (lt)	2006-07-10	2016-12-12	Esbatech, An Alcon Biomedical Research Unit Llc	Scfv antikūnai, pereinantys epitelio ir (arba) endotelio sluoksnius
JP2010509369A (ja)	2006-11-10	2010-03-25	ジェネンテックインコーポレイテッド	加齢黄斑変性症を処置するための方法
US7553486B2 (en)	2006-11-13	2009-06-30	Paul Theodore Finger	Anti-VEGF treatment for radiation-induced vasculopathy
JP2010513566A (ja)	2006-12-19	2010-04-30	ジェネンテック，インコーポレイテッド	アジュバント療法およびネオアジュバント療法のためのｖｅｇｆ特異的アンタゴニストと初期ステージ腫瘍の治療
EP3202786A3 (en)	2007-03-12	2017-10-11	ESBATech, an Alcon Biomedical Research Unit LLC	Sequence based engineering and optimization of single chain antibodies
CA2688434A1 (en)	2007-06-06	2008-12-11	Domantis Limited	Polypeptides, antibody variable domains and antagonists
NZ580530A (en)	2007-06-06	2012-04-27	Domantis Ltd	Anti vegf polypeptides, antibody variable domains and antagonists
CA2689941C (en)	2007-06-25	2019-10-29	Esbatech Ag	Methods of modifying antibodies, and modified antibodies with improved functional properties
JP5506670B2 (ja)	2007-06-25	2014-05-28	エスバテック − アノバルティスカンパニーエルエルシー	単鎖抗体の配列に基づくエンジニアリング及び最適化
CA2719400C (en) *	2008-03-26	2017-11-14	Epitomics, Inc.	Anti-vegf antibody
ES2677003T3 (es) *	2008-06-25	2018-07-27	Esbatech, An Alcon Biomedical Research Unit Llc	Humanización de anticuerpos de conejo utilizando un marco universal de anticuerpos
KR102013220B1 (ko)	2008-06-25	2019-08-23	에스바테크 - 어 노바티스 컴파니 엘엘씨	Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체
PL3241843T3 (pl)	2008-06-25	2021-12-27	Novartis Ag	Optymalizacja rozpuszczalności cząsteczek immunowiążących
EP2769711A1 (en) *	2008-07-10	2014-08-27	ESBATech, an Alcon Biomedical Research Unit LLC	Methods and Compositions for Enhanced Delivery of Macromolecules
MX2012005345A (es) *	2009-12-23	2012-06-08	Esbatech Alcon Biomed Res Unit	Metodo para disminuir inmunogenicidad.

2009
- 2009-06-25 KR KR1020117001961A patent/KR102013220B1/ko active Active
- 2009-06-25 KR KR1020187000324A patent/KR20180005753A/ko not_active Abandoned
- 2009-06-25 WO PCT/CH2009/000220 patent/WO2009155724A2/en not_active Ceased
- 2009-06-25 HU HUE20158159A patent/HUE068894T2/hu unknown
- 2009-06-25 PL PL17151756T patent/PL3216803T3/pl unknown
- 2009-06-25 CN CN200980124313.5A patent/CN102143976B/zh active Active
- 2009-06-25 AU AU2009264565A patent/AU2009264565C1/en active Active
- 2009-06-25 PL PL09768693T patent/PL2307454T3/pl unknown
- 2009-06-25 DK DK09768693.5T patent/DK2307454T3/en active
- 2009-06-25 ES ES09768693.5T patent/ES2622470T3/es active Active
- 2009-06-25 KR KR1020207026266A patent/KR102296443B1/ko active Active
- 2009-06-25 SI SI200931647A patent/SI2307454T1/sl unknown
- 2009-06-25 MX MX2017006583A patent/MX392435B/es unknown
- 2009-06-25 CA CA3020290A patent/CA3020290A1/en active Pending
- 2009-06-25 KR KR1020177012884A patent/KR101817284B1/ko active Active
- 2009-06-25 LT LTEP09768693.5T patent/LT2307454T/lt unknown
- 2009-06-25 EP EP20158159.2A patent/EP3722310B1/en active Active
- 2009-06-25 JP JP2011515049A patent/JP5956752B2/ja active Active
- 2009-06-25 SI SI200932061T patent/SI3216803T1/sl unknown
- 2009-06-25 BR BRPI0914251-7A patent/BRPI0914251B1/pt active IP Right Grant
- 2009-06-25 FI FIEP20158159.2T patent/FI3722310T3/fi active
- 2009-06-25 CN CN201910338494.7A patent/CN110372792A/zh active Pending
- 2009-06-25 KR KR1020187024733A patent/KR102095257B1/ko active Active
- 2009-06-25 CN CN201510205513.0A patent/CN104961828B/zh active Active
- 2009-06-25 DK DK20158159.2T patent/DK3722310T3/da active
- 2009-06-25 KR KR1020197022648A patent/KR102157097B1/ko active Active
- 2009-06-25 KR KR1020167030125A patent/KR101737466B1/ko active Active
- 2009-06-25 HR HRP20241467TT patent/HRP20241467T1/hr unknown
- 2009-06-25 HU HUE17151756A patent/HUE050230T2/hu unknown
- 2009-06-25 SI SI200932208T patent/SI3722310T1/sl unknown
- 2009-06-25 PT PT97686935T patent/PT2307454T/pt unknown
- 2009-06-25 PL PL20158159.2T patent/PL3722310T3/pl unknown
- 2009-06-25 DK DK17151756.8T patent/DK3216803T3/da active
- 2009-06-25 EP EP09768693.5A patent/EP2307454B1/en active Active
- 2009-06-25 LT LTEP20158159.2T patent/LT3722310T/lt unknown
- 2009-06-25 US US13/000,423 patent/US8349322B2/en active Active
- 2009-06-25 PT PT171517568T patent/PT3216803T/pt unknown
- 2009-06-25 CA CA2727839A patent/CA2727839C/en active Active
- 2009-06-25 HR HRP20170615TT patent/HRP20170615T1/hr unknown
- 2009-06-25 RU RU2014132888A patent/RU2588467C3/ru active Protection Beyond IP Right Term
- 2009-06-25 PT PT201581592T patent/PT3722310T/pt unknown
- 2009-06-25 ES ES17151756T patent/ES2793008T3/es active Active
- 2009-06-25 HU HUE09768693A patent/HUE032894T2/hu unknown
- 2009-06-25 MX MX2011000011A patent/MX2011000011A/es active IP Right Grant
- 2009-06-25 EP EP17151756.8A patent/EP3216803B1/en active Active
- 2009-06-25 MX MX2013004871A patent/MX347972B/es unknown
- 2009-06-25 RU RU2011102583A patent/RU2531523C3/ru active
- 2009-06-25 LT LTEP17151756.8T patent/LT3216803T/lt unknown
- 2009-06-25 KR KR1020157032314A patent/KR101671886B1/ko active Active
- 2009-06-25 ES ES20158159T patent/ES2998307T3/es active Active
2010
- 2010-11-30 ZA ZA2010/08594A patent/ZA201008594B/en unknown
- 2010-12-23 CL CL2010001544A patent/CL2010001544A1/es unknown
2012
- 2012-12-07 US US13/708,575 patent/US9090684B2/en active Active
2013
- 2013-07-19 RU RU2013133802/10A patent/RU2013133802A/ru not_active Application Discontinuation
2014
- 2014-04-21 JP JP2014087194A patent/JP6100199B2/ja active Active
2015
- 2015-02-27 JP JP2015037794A patent/JP2015134792A/ja active Pending
- 2015-06-16 US US14/741,430 patent/US9873737B2/en active Active
- 2015-07-20 PH PH12015501593A patent/PH12015501593A1/en unknown
2016
- 2016-05-18 RU RU2016119152A patent/RU2648152C2/ru active
- 2016-12-28 JP JP2016255720A patent/JP6527128B2/ja active Active
2017
- 2017-04-12 CY CY20171100436T patent/CY1118829T1/el unknown
- 2017-11-16 US US15/814,784 patent/US10590193B2/en active Active
2018
- 2018-02-05 JP JP2018018375A patent/JP6821612B2/ja active Active
- 2018-02-16 RU RU2018105866A patent/RU2696972C1/ru active
2019
- 2019-05-13 JP JP2019090735A patent/JP6978468B2/ja active Active
- 2019-06-27 RU RU2019120079A patent/RU2747735C3/ru active
2020
- 2020-01-31 US US16/779,028 patent/US20200172608A1/en not_active Abandoned
- 2020-05-19 HR HRP20200814TT patent/HRP20200814T1/hr unknown
- 2020-06-05 CY CY20201100507T patent/CY1123028T1/el unknown
- 2020-07-23 LT LTPA2020004C patent/LTC2307454I2/lt unknown
- 2020-07-27 HU HUS2000028C patent/HUS2000028I1/hu unknown
- 2020-07-28 NL NL301058C patent/NL301058I2/nl unknown
- 2020-07-30 CY CY2020026C patent/CY2020026I1/el unknown
- 2020-08-04 NO NO2020021C patent/NO2020021I1/no unknown
2021
- 2021-11-11 JP JP2021184262A patent/JP7171877B6/ja active Active
2023
- 2023-02-07 US US18/165,845 patent/US20250066462A1/en active Pending

Also Published As

Publication number	Publication date
HUE032894T2 (hu)	2017-11-28
HUE050230T2 (hu)	2020-11-30
RU2588467C3 (ru)	2021-10-20
US20120014958A1 (en)	2012-01-19
RU2531523C3 (ru)	2022-05-04
EP3722310A1 (en)	2020-10-14
RU2019120079A3 (nl)	2020-12-28
KR20180005753A (ko)	2018-01-16
LT3722310T (lt)	2024-12-27
CA3020290A1 (en)	2009-12-30
CN110372792A (zh)	2019-10-25
CN104961828B (zh)	2019-03-26
JP2017055774A (ja)	2017-03-23
ES2998307T3 (en)	2025-02-19
NO2020021I1 (no)	2020-08-04
RU2696972C1 (ru)	2019-08-07
NL301058I1 (nl)	2020-07-31
HUE068894T2 (hu)	2025-02-28
PL3722310T3 (pl)	2025-01-20
RU2011102583A (ru)	2012-07-27
JP2019162127A (ja)	2019-09-26
HRP20170615T1 (hr)	2017-07-28
HK1150844A1 (en)	2012-01-13
KR20170057462A (ko)	2017-05-24
JP6821612B2 (ja)	2021-01-27
CL2010001544A1 (es)	2012-02-03
SI3722310T1 (sl)	2025-01-31
JP2022020782A (ja)	2022-02-01
JP2014158491A (ja)	2014-09-04
HRP20200814T1 (hr)	2020-08-07
LTPA2020004I1 (lt)	2020-08-10
KR20150132602A (ko)	2015-11-25
LTC2307454I2 (lt)	2021-05-25
PL2307454T3 (pl)	2017-07-31
ES2622470T3 (es)	2017-07-06
CY2020026I2 (el)	2020-11-25
HUS2000028I1 (hu)	2020-08-28
US9873737B2 (en)	2018-01-23
CA2727839C (en)	2018-11-20
RU2531523C9 (ru)	2015-04-10
US10590193B2 (en)	2020-03-17
DK2307454T3 (en)	2017-04-24
KR102296443B1 (ko)	2021-09-01
PH12015501593A1 (en)	2015-12-14
US20180072802A1 (en)	2018-03-15
KR20180098705A (ko)	2018-09-04
KR102095257B1 (ko)	2020-04-01
AU2009264565A1 (en)	2009-12-30
KR20200108922A (ko)	2020-09-21
US8349322B2 (en)	2013-01-08
RU2648152C2 (ru)	2018-03-22
US20150274820A1 (en)	2015-10-01
US20250066462A1 (en)	2025-02-27
MX347972B (es)	2017-05-22
JP6527128B2 (ja)	2019-06-05
EP3216803A1 (en)	2017-09-13
CY1118829T1 (el)	2018-01-10
RU2531523C2 (ru)	2014-10-20
KR20160128458A (ko)	2016-11-07
PL3216803T3 (pl)	2020-10-19
RU2019120079A (ru)	2020-12-28
LT3216803T (lt)	2020-06-10
BRPI0914251B1 (pt)	2022-07-19
RU2013133802A (ru)	2015-01-27
MX392435B (es)	2025-03-19
WO2009155724A3 (en)	2010-04-01
DK3216803T3 (da)	2020-06-02
HRP20241467T1 (hr)	2025-01-03
PT2307454T (pt)	2017-04-26
KR101737466B1 (ko)	2017-05-18
RU2014132888A (ru)	2015-12-10
CY1123028T1 (el)	2021-10-29
RU2747735C2 (ru)	2021-05-13
CN104961828A (zh)	2015-10-07
CN102143976B (zh)	2015-11-25
EP3722310B1 (en)	2024-08-28
EP2307454B1 (en)	2017-01-18
JP7171877B6 (ja)	2024-02-06
KR101817284B1 (ko)	2018-01-11
CA2727839A1 (en)	2009-12-30
KR101671886B1 (ko)	2016-11-04
KR102013220B1 (ko)	2019-08-23
US20200172608A1 (en)	2020-06-04
EP3216803B1 (en)	2020-03-11
JP2018108081A (ja)	2018-07-12
SI3216803T1 (sl)	2020-07-31
ES2793008T3 (es)	2020-11-12
PT3722310T (pt)	2024-11-12
SI2307454T1 (sl)	2017-05-31
BRPI0914251A2 (pt)	2021-01-05
JP6100199B2 (ja)	2017-03-22
WO2009155724A2 (en)	2009-12-30
ZA201008594B (en)	2012-02-29
JP2011525359A (ja)	2011-09-22
EP2307454A2 (en)	2011-04-13
US9090684B2 (en)	2015-07-28
AU2009264565B2 (en)	2014-05-08
PT3216803T (pt)	2020-06-16
MX2011000011A (es)	2011-09-27
LT2307454T (lt)	2017-05-25
FI3722310T3 (fi)	2024-11-27
RU2016119152A (ru)	2017-11-21
JP5956752B2 (ja)	2016-07-27
RU2747735C3 (ru)	2022-05-04
KR102157097B1 (ko)	2020-09-18
CY2020026I1 (el)	2020-11-25
JP6978468B2 (ja)	2021-12-08
CN102143976A (zh)	2011-08-03
KR20190092630A (ko)	2019-08-07
JP2015134792A (ja)	2015-07-27
JP7171877B2 (ja)	2022-11-15
AU2009264565C1 (en)	2022-01-27
KR20110028518A (ko)	2011-03-18
US20140004114A1 (en)	2014-01-02
DK3722310T3 (da)	2024-11-18

Publication	Publication Date	Title
NO2020021I1 (no)	2020-08-04	Brolucizumab
DK2342317T3 (da)	2013-03-18	Hængende-dråbe-plade
BRPI0907376A2 (pt)	2015-07-14	Fotobiorretador
EP2258938A4 (en)	2012-09-05	TYPE VEHICLE TO BE PROVIDED
EP2368526A4 (en)	2015-04-15	INSERTION TOOL FOR AN INTRAOCULAR LENS
BRPI0914649A2 (pt)	2015-07-07	Piprazolo-quinazolinas
EP2336764A4 (en)	2011-09-28	LIQUID CHROMATOGRAPH
DE602008003972D1 (de)	2011-01-27	Sitzrücklehnungsmechanismus
DE602008003521D1 (de)	2010-12-30	Sitzrücklehnungsmechanismus
EP2320913A4 (en)	2012-10-03	NUCLEIC ACID APTAMERS
DK2342454T3 (da)	2013-10-28	Vindkraftanlæg
DK2336132T3 (da)	2014-04-07	Morpholinpurinderivat
DK2335031T3 (da)	2019-08-26	In-line-måler
EP2368115A4 (en)	2012-08-22	ANALYTE DETECTION TEST
EP2308156A4 (en)	2014-02-19	STEP ACTUATOR
DK2379557T3 (da)	2012-12-17	Aminopyrazol-forbindelse
DK2271613T3 (da)	2014-07-14	Hydroxymethylcyklohexylaminer
DE602008003970D1 (de)	2011-01-27	Strahlstromkalibriersystem
EP2377648A4 (en)	2016-11-30	GRINDING MACHINE INNER TOOTH WHEEL
EP2248964A4 (en)	2011-08-31	DRILLING / TERMINAL DEVICE
EP2318641A4 (en)	2015-12-09	TOOL FOR CENTERING FOR DRILLING ENCLOSURE
BRPI0907522A2 (pt)	2019-09-24	biarlamidas
DE112009000183A5 (de)	2011-02-03	Sicherheitsvorreiber
DE602009000862D1 (de)	2011-04-28	Gehwagenbremse
EP2245356A4 (en)	2012-10-24	STRUCTURAL FIBER STRING, IMPREGNATED WITH RESIN